LQDA cites YUTREPIA growth and pipeline expansion powering profitability
LQDA says YUTREPIA’s launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. It points to multiple late-stage trials, including L606, and expansion into PH-COPD and Raynaud's.
YUTREPIA's launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. The pipeline includes multiple late-stage trials, notably for L606, and expansion into new indications like PH-COPD and Raynaud's. Financial performance is robust, with a focus on…